 BeyondSpring Inc. the Company or BeyondSpring BYSI, a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company presented clinical data on BeyondSprings first-in-class, late-stage asset, Plinabulin, showing potent CD34 progenitor cell mobilization from bone marrow, which has broad applications for stem cell-based therapies, gene therapy and regenerative medicine. Dr. Ramon Mohanlal, BeyondSprings Chief Medical Officer and Executive Vice President, Research and Development, presented this new data as a poster at this years ISSCR Annual Meeting. 